Alzheimer Society of Ontario

Experience the Joy of Giving with the 24 GOOD DEEDS Charity Advent Calendar

Retrieved on: 
Monday, October 16, 2023

Toronto, Ontario, Oct. 16, 2023 (GLOBE NEWSWIRE) -- As the holiday season approaches, the 24 GOOD DEEDS Charity Advent Calendar returns for its fourth consecutive year, continuing its mission to support impactful charitable causes in Canada and abroad.

Key Points: 
  • Toronto, Ontario, Oct. 16, 2023 (GLOBE NEWSWIRE) -- As the holiday season approaches, the 24 GOOD DEEDS Charity Advent Calendar returns for its fourth consecutive year, continuing its mission to support impactful charitable causes in Canada and abroad.
  • This unique calendar is all about giving back to local and global charity projects in a meaningful way.
  • For a $24 donation, you'll receive this very special Advent Calendar.
  • Your contribution to 24 GOOD DEEDS makes a real impact in the lives of those in need.

10 Ways to Reduce Your Risk of Dementia

Retrieved on: 
Monday, September 11, 2023

TORONTO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- While some risk factors for dementia are genetic, there are many lifestyle factors that can help reduce your risk.

Key Points: 
  • TORONTO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- While some risk factors for dementia are genetic, there are many lifestyle factors that can help reduce your risk.
  • By taking care of your physical and mental health, you may be able to reduce your risk of developing dementia, or delay its onset.
  • Even in later life, these steps can improve your brain health and reduce your dementia risk.
  • If you are living with dementia or caring for someone living with dementia, free support is available by contacting your local Alzheimer Society.

Alzheimer Society Research Program now open

Retrieved on: 
Friday, September 8, 2023

TORONTO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Each year, the Alzheimer Society Research Program funds the best and brightest dementia researchers across Canada by providing millions of dollars in awards and grants.

Key Points: 
  • TORONTO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Each year, the Alzheimer Society Research Program funds the best and brightest dementia researchers across Canada by providing millions of dollars in awards and grants.
  • The Alzheimer Society Research Program (ASRP) is led by the Alzheimer Society of Canada, with lead partner Brain Canada Foundation, and support from Saskatchewan Health Research Foundation and Fonds de recherche du Québec – Santé.
  • “The ASRP is one of our flagship initiatives each year,” said Dr. Louise Scrocchi, Research Executive, Alzheimer Society of Canada.
  • “We take great pride in collaborating with our partners, including Alzheimer Society of Canada, to support and drive groundbreaking research in the field of dementia,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Alzheimer Society of Canada invests nearly $6 million to support innovative dementia research

Retrieved on: 
Thursday, July 20, 2023

“We are setting the standard for dementia research in this country,” says Christopher Barry, Chief Executive Officer, Alzheimer Society of Canada.

Key Points: 
  • “We are setting the standard for dementia research in this country,” says Christopher Barry, Chief Executive Officer, Alzheimer Society of Canada.
  • The Alzheimer Society Research Program is changing dementia research in Canada.
  • This funding has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada), Brain Canada Foundation, and Alzheimer Society of Canada.
  • The Alzheimer Society Research Program funds dementia research across Canada.

Alzheimer Society of Ontario Welcomes Latest Positive Trial Results for Alzheimer’s Disease Treatment

Retrieved on: 
Monday, July 17, 2023

TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario is expressing its optimism at today’s release of full clinical trial data from the phase three trial of donanemab, a treatment candidate for Alzheimer’s disease developed by Eli Lilly.

Key Points: 
  • TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario is expressing its optimism at today’s release of full clinical trial data from the phase three trial of donanemab, a treatment candidate for Alzheimer’s disease developed by Eli Lilly.
  • “Today’s data is the latest in a string of good news in the world of Alzheimer’s disease research,” said Cathy Barrick, CEO of the Alzheimer Society of Ontario.
  • “For the first time ever, there are now multiple promising treatment options for people at the earlier stages of Alzheimer’s disease.
  • Today’s full results show that these reductions are greater among trial participants with mild cognitive impairment, with cognitive decline slowed by 60%.

Care Partner Mobile Application Launch Party

Retrieved on: 
Friday, July 7, 2023

Toronto, July 07, 2023 (GLOBE NEWSWIRE) -- On July 7th, the Alzheimer Society of Toronto will launch the Care Partner Mobile Application on both the Apple and Google Play stores with a launch party.

Key Points: 
  • Toronto, July 07, 2023 (GLOBE NEWSWIRE) -- On July 7th, the Alzheimer Society of Toronto will launch the Care Partner Mobile Application on both the Apple and Google Play stores with a launch party.
  • The Care Partner App, previously known as the Dementia Talk App – is an award-winning mobile application created by the Reitman Centre at Mount Sinai Hospital.
  • The Care Partner mobile application uses tools and resources to support the caregiver of someone living with dementia, with the goal of promoting everyone's wellbeing.
  • Caregivers or care partners of people living with dementia are invited to attend the launch party which will be held from 10 am – 12 pm at the Alzheimer Society of Toronto office at 20 Eglinton Avenue West, on the 16th floor.

Breakthrough in Alzheimer’s Disease Treatment: Alzheimer Society of Ontario Applauds US Approval of Game-Changing Disease-Modifying Therapy

Retrieved on: 
Thursday, July 6, 2023

TORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario welcomes today’s US FDA decision to grant full approval to lecanemab (brand name: Leqembi), a disease-modifying therapy for Alzheimer’s disease.

Key Points: 
  • TORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario welcomes today’s US FDA decision to grant full approval to lecanemab (brand name: Leqembi), a disease-modifying therapy for Alzheimer’s disease.
  • This marks the first full approval of any treatment for Alzheimer’s disease globally, and marks the latest positive step forward for research into therapeutic and diagnosis options.
  • “Helplessness is steadily giving way to hope,” said Cathy Barrick, CEO of the Alzheimer Society of Ontario.
  • “We have had years of advance notice that treatment options for Alzheimer’s disease are coming to Ontario,” continued Ms. Barrick.

Alzheimer Society of Ontario Welcomes Health Canada Approval of New Test for Alzheimer’s Disease Detection

Retrieved on: 
Thursday, June 8, 2023

TORONTO, June 08, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario is encouraged by today’s Health Canada approval of three biomarker tests developed by Roche Diagnostics to detect indicators of Alzheimer’s disease pathology.

Key Points: 
  • TORONTO, June 08, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario is encouraged by today’s Health Canada approval of three biomarker tests developed by Roche Diagnostics to detect indicators of Alzheimer’s disease pathology.
  • The tests are an additional, less costly option for health care providers and families to gain information and make advanced care decisions with greater certainty.
  • “With over 275,000 Ontarians living with dementia today—and three times that number within the next 30 years—Ontario needs new and innovative options for detecting and diagnosing Alzheimer’s disease,” said Cathy Barrick, CEO of the Alzheimer Society of Ontario.
  • “Researchers and industry have done their part, and ground-breaking detection and treatment options will soon be coming to market.

Alzheimer Society of Ontario Applauds First Step Towards Approved Treatment for Alzheimer’s Disease in Canada

Retrieved on: 
Wednesday, May 17, 2023

If approved, Leqembi would be Canada’s first treatment for Alzheimer’s disease—not just its symptoms.

Key Points: 
  • If approved, Leqembi would be Canada’s first treatment for Alzheimer’s disease—not just its symptoms.
  • “Two years ago the world had no approved treatments for Alzheimer’s disease.
  • It is vital that we get the introduction of this first treatment right.”
    Research out of the University of Southern California released last year, sponsored by the Alzheimer Society of Ontario, found that Ontario is not ready for the now-foreseeable arrival of an approved treatment for Alzheimer’s disease.
  • To be most effective Leqembi, along with two other promising treatments for Alzheimer’s disease, must be administered early in disease progression.

Alzheimer Society of Ontario Welcomes Another Promising Treatment for Alzheimer’s Disease

Retrieved on: 
Wednesday, May 3, 2023

The United States has two approved treatments to slow progression of the disease, but currently Canada has none,” explains Cathy Barrick, CEO of the Alzheimer Society of Ontario.

Key Points: 
  • The United States has two approved treatments to slow progression of the disease, but currently Canada has none,” explains Cathy Barrick, CEO of the Alzheimer Society of Ontario.
  • Our federal and provincial governments must get to work immediately to prepare for the arrival of new treatment options for Alzheimer’s disease.
  • As things stand today, Ontario would not be able to introduce a treatment for Alzheimer’s disease even if one were approved.
  • That won’t be good enough in the near future: treatment options will be costly and come with potentially fatal side effects.